PMID- 9798264
OWN - NLM
STAT- MEDLINE
DCOM- 19990108
LR  - 20031114
IS  - 1230-6002 (Print)
IS  - 1230-6002 (Linking)
VI  - 50
IP  - 2
DP  - 1998 Mar-Apr
TI  - Central action of glucagon.
PG  - 125-33
AB  - The central action of the peptide of intestinal tract, glucagon, was studied in 
      Albino Swiss mice (20-25 g) and Wistar rats (200-220 g). Glucagon was injected 
      intracerebroventricularly (icv) at the dose of 0.25, 0.5 and 1 microgram in 1 
      microliter of distilled water per mouse or 5 micrograms in 5 microliters per rat. 
      It was found that glucagon administered icv increased glucose content in the 
      peripheral blood serum. Behavioral studies have shown that glucagon diminished 
      spontaneous locomotor activity in rats and mice, impaired exploratory activity 
      and reduced amphetamine-induced hyperactivity. The results were not dependent on 
      hyperglycaemia because the administration of 20% glucose solution po did not 
      cause above effects. In addition, glucagon potentiated cataleptogenic effects of 
      haloperidol. Icv injection of glucagon did not change the pain sensitivity or 
      seizure susceptibility. The substance did not show the anxiolytic properties and 
      did not affect the duration of hexobarbital-induced sleep. In biochemical studies 
      it was found that glucagon injected icv induced the decrease in GABA content 
      while the DA content was increased. The utilization of DA was not changed. The 
      obtained results indicated, that glucagon injected icv exerted the central 
      action, which was manifested by the central regulation of glucose level in the 
      periphery. Moreover, glucagon inhibited the locomotor and exploratory activity as 
      well as the amphetamine-induced hyperactivity and enhanced haloperidol-induced 
      catalepsy. These effect could be connected with the inhibition of the central 
      dopaminergic structures by glucagon.
FAU - Morawska, D
AU  - Morawska D
AD  - Department of Pharmacology, Medical University, Lublin, Poland.
FAU - Sieklucka-Dziuba, M
AU  - Sieklucka-Dziuba M
FAU - Kleinrok, Z
AU  - Kleinrok Z
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol J Pharmacol
JT  - Polish journal of pharmacology
JID - 9313882
RN  - 0 (Analgesics)
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Anticonvulsants)
RN  - 0 (Blood Glucose)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Analgesics/pharmacology
MH  - Animals
MH  - Anti-Anxiety Agents/pharmacology
MH  - Anticonvulsants/pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Blood Glucose/metabolism
MH  - Brain Chemistry/drug effects
MH  - Catalepsy/chemically induced/psychology
MH  - Central Nervous System/*drug effects
MH  - Exploratory Behavior/drug effects
MH  - Female
MH  - Glucagon/administration & dosage/*pharmacology
MH  - Injections, Intraventricular
MH  - Male
MH  - Mice
MH  - Motor Activity/drug effects
MH  - Psychomotor Performance/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Reaction Time/drug effects
MH  - Sleep/drug effects
EDAT- 1998/11/03 00:00
MHDA- 1998/11/03 00:01
CRDT- 1998/11/03 00:00
PHST- 1998/11/03 00:00 [pubmed]
PHST- 1998/11/03 00:01 [medline]
PHST- 1998/11/03 00:00 [entrez]
PST - ppublish
SO  - Pol J Pharmacol. 1998 Mar-Apr;50(2):125-33.